HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Safety of low-dose aspirin in endovascular treatment for intracranial atherosclerotic stenosis.

AbstractOBJECTIVES:
To evaluate the safety of low-dose aspirin plus clopidogrel versus high-dose aspirin plus clopidogrel in prevention of vascular risk within 90 days of duration of dual antiplatelet therapy in patients treated with intracranial endovascular treatment.
METHODS:
From January 2012 to December 2013, this prospective and observational study enrolled 370 patients with symptomatic intracranial atherosclerotic stenosis of ≥70% with poor collateral undergoing intracranial endovascular treatment. Antiplatelet therapy consists of aspirin, at a low-dose of 100 mg or high-dose of 300 mg daily; clopidogrel, at a dose of 75 mg daily for 5 days before endovascular treatment. The dual antiplatelet therapy continued for 90 days after intervention. The study endpoints include acute thrombosis, subacute thrombosis, stroke or death within 90 days after intervention.
RESULTS:
Two hundred and seventy three patients received low-dose aspirin plus clopidogrel and 97 patients received high-dose aspirin plus clopidogrel before intracranial endovascular treatment. Within 90 days after intervention, there were 4 patients (1.5%) with acute thrombosis, 5 patients (1.8%) with subacute thrombosis, 17 patients (6.2%) with stroke, and 2 death (0.7%) in low-dose aspirin group, compared with no patient (0%) with acute thrombosis, 2 patient (2.1%) with subacute thrombosis, 6 patients (6.2%) with stroke, and 2 death (2.1%) in high-dose aspirin group, and there were no significant difference in all study endpoints between two groups.
CONCLUSION:
Low-dose aspirin plus clopidogrel is comparative in safety with high-dose aspirin plus clopidogrel within 90 days of duration of dual antiplatelet therapy in patients treated with intracranial endovascular treatment.
AuthorsNing Ma, Ziqi Xu, Dapeng Mo, Feng Gao, Kun Gao, Xuan Sun, Xiaotong Xu, Lian Liu, Ligang Song, Tiejun Wang, Xingquan Zhao, Yilong Wang, Yongjun Wang, Zhongrong Miao
JournalPloS one (PLoS One) Vol. 9 Issue 8 Pg. e105252 ( 2014) ISSN: 1932-6203 [Electronic] United States
PMID25144449 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Platelet Aggregation Inhibitors
  • Clopidogrel
  • Ticlopidine
  • Aspirin
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Aspirin (administration & dosage, adverse effects, therapeutic use)
  • Clopidogrel
  • Constriction, Pathologic (drug therapy)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Platelet Aggregation Inhibitors (administration & dosage, adverse effects, therapeutic use)
  • Prospective Studies
  • Ticlopidine (administration & dosage, analogs & derivatives, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: